Bailong Chuangyuan(SH:605016) Xinda Securities·2025-10-30 08:01Investment Rating - The investment rating for the company is "Buy" [1][2]. Core Insights - The company has shown excellent performance in its financial results, with a revenue of 969 million yuan for the first three quarters of 2025, representing a year-on-year increase of 18.10%. The net profit attributable to the parent company reached 265 million yuan, up 44.93% year-on-year [2][4]. - The gross profit margin has significantly improved, reaching 44.46% in Q3, an increase of 11.94 percentage points year-on-year, driven by product structure optimization and the release of new production capacities [4]. - The approval process for D-allohexose is progressing, with expectations for the market to officially open next year, potentially leading to new revenue streams for the company [4]. Financial Performance Summary - For 2025, the company is projected to achieve total revenue of 1.337 billion yuan, with a year-on-year growth rate of 16.1%. The net profit attributable to the parent company is expected to be 358 million yuan, reflecting a growth rate of 45.7% [5]. - The gross profit margin is forecasted to be 41.0% in 2025, with a return on equity (ROE) of 17.6% [5]. - The earnings per share (EPS) for 2025 is estimated at 0.85 yuan, with a price-to-earnings (P/E) ratio of 23.27 times [5]. Product and Market Analysis - The company’s product lines, including prebiotics, dietary fibers, and healthy sweeteners, have shown steady revenue growth, with Q3 revenues of 96.45 million yuan, 171 million yuan, and 43.22 million yuan, respectively [4]. - Domestic revenue in Q3 was 100 million yuan, down 2.80% year-on-year, while international revenue reached 208 million yuan, up 17.87% year-on-year, indicating strong overseas market performance [4].